CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

All Therapeutic Areas

Metabolic & Endocrine

93 drugs in pipeline from 10 companies

93

Drugs in Pipeline

10

Companies

9

Upcoming Catalysts

93

Phase 3 Trials

Upcoming Catalysts
4d
LLYPhase 2

LY3549492 Phase 2 Results Expected

LY3549492275
Apr 15
CT.gov
00%
4d
AKROPhase 3

Efruxifermin Phase 3 Results Expected

Efruxifermin700
Apr 15
CT.gov
00%
4d
LLYPhase 2

Bimagrumab Phase 2 Results Expected

Bimagrumab240
Apr 15
CT.gov
00%
4d
VRDNPhase 3

VRDN-003 Phase 3 Results Expected

VRDN-003321
Apr 15
CT.gov
00%
4d
LPCNPhase 3

Placebo Phase 3 Results Expected

LPCN 1144 Formulation A80
Apr 15
CT.gov
00%
4d
LLYPhase 3
Positive

Retatrutide Phase 3 Results Expected

Retatrutide1,800
Apr 15
CT.gov
2w
NVOPhase 3
Negative

Semaglutide Phase 3 Results Expected

Semaglutide300
Apr 21
CT.gov
2w
NVOPhase 3
Negative

Cagrilintide Phase 3 Results Expected

Cagrilintide300
Apr 21
CT.gov
2w
RHHBYPhase 2

RO7795081 Phase 2 Results Expected

RO7795081340
Apr 23
CT.gov
00%
Pipeline by Phase
Phase 3
93
Related Conditions
diabetesobesitymetabolicthyroidhormoneendocrineinsulinglucosehba1cweight lossglp-1nafldnashfatty liverhyperlipidemiadyslipidemiaosteoporosis